Positive News SentimentPositive NewsNASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $28.23 +3.01 (+11.93%) (As of 07/8/2024 ET) Add Compare Share Share Today's Range$25.49▼$28.8850-Day Range$20.13▼$28.8752-Week Range$6.58▼$33.77Volume306,970 shsAverage Volume191,575 shsMarket Capitalization$828.55 millionP/E RatioN/ADividend YieldN/APrice Target$42.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Dianthus Therapeutics alerts: Email Address Dianthus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside51.6% Upside$42.83 Price TargetShort InterestBearish9.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.63Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.18) to ($2.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.02 out of 5 starsMedical Sector323rd out of 876 stocksPharmaceutical Preparations Industry143rd out of 416 stocks 4.6 Analyst's Opinion Consensus RatingDianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDianthus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dianthus Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.63% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DNTH. Previous Next 3.7 News and Social Media Coverage News SentimentDianthus Therapeutics has a news sentiment score of 1.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dianthus Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for DNTH on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.56% of the stock of Dianthus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. About Dianthus Therapeutics Stock (NASDAQ:DNTH)Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Read More DNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNTH Stock News HeadlinesJuly 8 at 1:50 AM | americanbankingnews.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $42.83 Consensus Price Target from AnalystsJuly 3, 2024 | americanbankingnews.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest UpdateJuly 8, 2024 | Weiss Ratings (Ad)The only way to play the AI boom?A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.June 29, 2024 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.3%June 29, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Dianthus Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DNTH)June 28, 2024 | globenewswire.comDianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)June 21, 2024 | seekingalpha.comDianthus Therapeutics: Complement System Candidate Not Sufficiently DeriskedJune 12, 2024 | globenewswire.comDianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)July 8, 2024 | Weiss Ratings (Ad)The only way to play the AI boom?A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.May 30, 2024 | globenewswire.comDianthus Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 21, 2024 | finance.yahoo.comCompanies Like Dianthus Therapeutics (NASDAQ:DNTH) Are In A Position To Invest In GrowthMay 17, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationMay 16, 2024 | msn.comH.C. Wainwright starts Dianthus as buy, cites lead drug candidateMay 10, 2024 | investorplace.comDNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsMay 8, 2024 | finance.yahoo.comDianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care ConferenceMay 3, 2024 | globenewswire.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 18, 2024 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Dianthus TherapeuticsSee More Headlines Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DNTH CUSIPN/A CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Target$42.83 High Stock Price Target$51.00 Low Stock Price Target$38.00 Potential Upside/Downside+53.8%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,560,000.00 Net MarginsN/A Pretax Margin-2,226.78% Return on Equity-20.82% Return on Assets-19.86% Debt Debt-to-Equity RatioN/A Current Ratio42.52 Quick Ratio42.52 Sales & Book Value Annual Sales$2.83 million Price / Sales288.83 Cash FlowN/A Price / Cash FlowN/A Book Value$11.40 per share Price / Book2.44Miscellaneous Outstanding Shares29,350,000Free Float24,489,000Market Cap$817.40 million OptionableNo Data Beta1.89 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Marino Garcia M.B.A. (Age 58)President, CEO, Secretary & Director Comp: $496.02kMr. Ryan Savitz (Age 35)CFO and Chief Business Officer & Treasurer Comp: $329.65kMr. Simrat Randhawa M.B.A. (Age 54)M.D., Chief Medical Officer Comp: $338.16kMr. Edward G. Carr (Age 55)Chief Accounting Officer Mr. Judson TaylorHead of Technical OperationsDr. Jeffrey Stavenhagen Ph.D.Chief Scientific OfficerMs. Jennifer Davis RuffVP and Head of Investor Relations & Corporate Affairs.Mr. Adam M. Veness Esq. (Age 38)Senior VP, General Counsel & Secretary Ms. Kristina MaximenkoChief People OfficerMs. Rashieda GluckHead of Clinical Development OperationsMore ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNBiohavenNYSE:BHVNHUTCHMEDNASDAQ:HCMAmicus TherapeuticsNASDAQ:FOLDTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 12,995 shares on 5/20/2024Ownership: 0.044%RA Capital Management L.P.Bought 2,333,000 shares on 5/17/2024Ownership: 7.949%Bain Capital Life Sciences Investors LLCBought 2,992,028 shares on 5/16/2024Ownership: 10.194%Janus Henderson Group PLCBought 375,044 shares on 5/16/2024Ownership: 1.278%StemPoint Capital LPBought 43,456 shares on 5/14/2024Ownership: 0.148%View All Insider TransactionsView All Institutional Transactions DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $10.40 at the beginning of the year. Since then, DNTH shares have increased by 171.6% and is now trading at $28.25. View the best growth stocks for 2024 here. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.11. The company earned $0.87 million during the quarter, compared to analyst estimates of $0.48 million. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DNTH) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersThe True Potential for Civil War…As you’ll see - all scenarios must be examined right now. Radical leftists mobilizing illegal immigrants, viol...Paradigm Press | SponsoredMarket timing expert: “The next hot AI projects are NOT on the stock market.”The next hot AI stocks — are not stocks at all. You can find them in a virtually unknown niche in the marke...Weiss Ratings | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
